Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 1;50(4):494-499.
doi: 10.1097/MPA.0000000000001799.

The Clinical Applicability of Primary Thromboprophylaxis in Ambulatory Patients With Pancreatic Cancer

Lyndsey Paige Sandow  1 , Laura A Cannon, Natalie Rose Weston  1 , Kyaw Lwin Aung  2 , Thein Hlaing Oo  3
Affiliations
Review

The Clinical Applicability of Primary Thromboprophylaxis in Ambulatory Patients With Pancreatic Cancer

Lyndsey Paige Sandow et al. Pancreas. .

Abstract

Thromboembolism is a leading cause of death in ambulatory patients with cancer. Patients with pancreatic adenocarcinoma have a very high risk of developing venous thromboembolism, especially within the first 6 months of diagnosis. Although primary thromboprophylaxis could reduce this risk, there are unresolved questions concerning choice of agents for anticoagulation, duration of anticoagulation treatment, and criteria for patient selection. Furthermore, the current clinical guidelines on primary thromboprophylaxis in ambulatory patients with pancreatic cancer are ambiguous. This review seeks out to understand and critically appraise the evidence supporting the use of primary thromboprophylaxis in patients with pancreatic cancer and its clinical applicability.

PubMed Disclaimer

Conflict of interest statement

T.H.O. served on the advisory board of the Bristol-Myers Squibb and Medical Education Speakers Network. Other authors declare no conflict of interest.

References

    1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost . 2007;5:632–634.
    1. Khorana AA, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer . 2013;119:648–655.
    1. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice Guideline Update. J Clin Oncol . 2020;38:496–520.
    1. Streiff MB, Holmstrom B, Angelini D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw . 2018;16:1289–1303.
    1. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol . 2011;22(suppl 6):vi85–vi92.

MeSH terms

LinkOut - more resources